866-997-4948(US-Canada Toll Free)

Critical Limb Ischemia-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 120 Pages

Critical Limb Ischemia-Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia-Pipeline Review, H2 2017, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.

Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 13, 4, 1 and 10 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Critical Limb Ischemia-Overview 6
Critical Limb Ischemia-Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Critical Limb Ischemia-Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Critical Limb Ischemia-Companies Involved in Therapeutics Development 23
AnGes MG Inc 23
apceth Biopharma GmbH 23
Athersys Inc 24
BiogenCell Ltd 24
Caladrius Biosciences Inc 24
Cynata Therapeutics Ltd 25
Hemostemix Inc 25
Histocell SL 26
ID Pharma Co Ltd 26
Integene International Holdings LLC 26
Juventas Therapeutics Inc 27
Kang Stem Biotech Co Ltd 27
Kasiak Research Pvt Ltd 27
Neurofx Inc 28
Nissan Chemical Industries Ltd 28
Pharmicell Co Ltd 29
Pluristem Therapeutics Inc 29
ReNeuron Group Plc 30
Symic Biomedical Inc 30
TikoMed AB 31
U.S. Stem Cell Inc 31
VESSL Therapeutics Ltd 31
ViroMed Co Ltd 32
Critical Limb Ischemia-Drug Profiles 33
ACP-01-Drug Profile 33
AdipoCell-Drug Profile 36
Alecmestencel-T-Drug Profile 39
ASCT-01-Drug Profile 40
beperminogene perplasmid-Drug Profile 41
BGC-101-Drug Profile 46
Biologic to Activate FGF2 for Critical Limb Ischemia-Drug Profile 47
Cell Therapy for Peripheral Arterial Disease and Coronary Artery Diseases-Drug Profile 48
Cellgram-CLI-Drug Profile 49
CLBS-12-Drug Profile 50
DVC-10101-Drug Profile 51
Gene Therapy for Critical Limb Ischemia-Drug Profile 53
HC-016-Drug Profile 54
JVS-100-Drug Profile 55
NFx-101-Drug Profile 60
NK-104 NP-Drug Profile 61
PF-05285401-Drug Profile 62
PLX-PAD-Drug Profile 74
Procell-Drug Profile 85
Protein to Agonize LRP5 and LRP6 for Critical Limb Ischemia and Myocardial Infarction-Drug Profile 86
Refacell-CLI-Drug Profile 87
Rejuveinix-Drug Profile 88
ReN-009-Drug Profile 89
SB-030-Drug Profile 91
Stem Cell Therapy for Cardiovacular Diseases-Drug Profile 93
Stem Cell Therapy for Critical Limb Ischemia-Drug Profile 95
Stem Cell Therapy for Critical Limb Ischemia-Drug Profile 96
Stem Cell Therapy for Critical Limb Ischemia-Drug Profile 97
TM-700-Drug Profile 98
TXA-302-Drug Profile 99
VM-202-Drug Profile 100
Critical Limb Ischemia-Dormant Projects 104
Critical Limb Ischemia-Discontinued Products 106
Critical Limb Ischemia-Product Development Milestones 107
Featured News & Press Releases 107
Appendix 116
Methodology 116
Coverage 116
Secondary Research 116
Primary Research 116
Expert Panel Validation 116
Contact Us 116
Disclaimer 117

List of Tables
Number of Products under Development for Critical Limb Ischemia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Critical Limb Ischemia-Pipeline by AnGes MG Inc, H2 2017
Critical Limb Ischemia-Pipeline by apceth Biopharma GmbH, H2 2017
Critical Limb Ischemia-Pipeline by Athersys Inc, H2 2017
Critical Limb Ischemia-Pipeline by BiogenCell Ltd, H2 2017
Critical Limb Ischemia-Pipeline by Caladrius Biosciences Inc, H2 2017
Critical Limb Ischemia-Pipeline by Cynata Therapeutics Ltd, H2 2017
Critical Limb Ischemia-Pipeline by Hemostemix Inc, H2 2017
Critical Limb Ischemia-Pipeline by Histocell SL, H2 2017
Critical Limb Ischemia-Pipeline by ID Pharma Co Ltd, H2 2017
Critical Limb Ischemia-Pipeline by Integene International Holdings LLC, H2 2017
Critical Limb Ischemia-Pipeline by Juventas Therapeutics Inc, H2 2017
Critical Limb Ischemia-Pipeline by Kang Stem Biotech Co Ltd, H2 2017
Critical Limb Ischemia-Pipeline by Kasiak Research Pvt Ltd, H2 2017
Critical Limb Ischemia-Pipeline by Neurofx Inc, H2 2017
Critical Limb Ischemia-Pipeline by Nissan Chemical Industries Ltd, H2 2017
Critical Limb Ischemia-Pipeline by Pharmicell Co Ltd, H2 2017
Critical Limb Ischemia-Pipeline by Pluristem Therapeutics Inc, H2 2017
Critical Limb Ischemia-Pipeline by ReNeuron Group Plc, H2 2017
Critical Limb Ischemia-Pipeline by Symic Biomedical Inc, H2 2017
Critical Limb Ischemia-Pipeline by TikoMed AB, H2 2017
Critical Limb Ischemia-Pipeline by U.S. Stem Cell Inc, H2 2017
Critical Limb Ischemia-Pipeline by VESSL Therapeutics Ltd, H2 2017
Critical Limb Ischemia-Pipeline by ViroMed Co Ltd, H2 2017
Critical Limb Ischemia-Dormant Projects, H2 2017
Critical Limb Ischemia-Dormant Projects, H2 2017 (Contd..1), H2 2017
Critical Limb Ischemia-Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Critical Limb Ischemia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *